 Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across multiple tumor types Enrollment in multi-dosing cohorts continues Fusion also reported preclinical data showing the combination of FPI-1434 with olaparib resulting in synergistic efficacy against colorectal and lung cancer xenografts, and combination with immune checkpoint inhibitors demonstrated enhanced efficacy in colorectal cancer models Data featured in oral sessions and posters at the SNMMI 2021 Virtual Annual Meeting HAMILTON, Ontario and BOSTON, June 14, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging SNMMI Virtual Annual Meeting. The presentations and posters highlight the potential of Fusions targeted alpha therapies TATs to enable delivery of alpha particle emitting isotopes 225Ac to targeted tumor cells. 